This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Earnings Preview: Alignment Healthcare (ALHC) Q1 Earnings Expected to Decline
by Zacks Equity Research
Alignment Healthcare (ALHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Bausch + Lomb (BLCO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Bausch + Lomb (BLCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BLCO vs. AVTR: Which Stock Is the Better Value Option?
by Zacks Equity Research
BLCO vs. AVTR: Which Stock Is the Better Value Option?
All You Need to Know About Bausch + Lomb (BLCO) Rating Upgrade to Buy
by Zacks Equity Research
Bausch + Lomb (BLCO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BLCO or AVTR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BLCO vs. AVTR: Which Stock Is the Better Value Option?
BLCO or AVTR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BLCO vs. AVTR: Which Stock Is the Better Value Option?
Surging Earnings Estimates Signal Upside for Bausch + Lomb (BLCO) Stock
by Zacks Equity Research
Bausch + Lomb (BLCO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Compared to Estimates, Bausch + Lomb (BLCO) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Bausch + Lomb (BLCO) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Seeking Clues to Bausch + Lomb (BLCO) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Bausch + Lomb (BLCO), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.
Will Bausch + Lomb (BLCO) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Bausch + Lomb (BLCO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Bausch + Lomb (BLCO) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Bausch + Lomb (BLCO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bausch + Lomb (BLCO) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Bausch + Lomb (BLCO) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Analysts Estimate Organon (OGN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bausch + Lomb (BLCO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Bausch + Lomb (BLCO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aldeyra (ALDX) Plummets on Dry Eye Disease Drug's Setback
by Zacks Equity Research
Aldeyra's (ALDX) new drug application for dry eye disease unlikely to be approved by the FDA due to its lack of efficacy.
Novartis (NVS) Spins off Sandoz, Reiterates Annual Outlook
by Zacks Equity Research
Novartis (NVS) separates Sandoz into an independent company. The company reaffirms the previously provided guidance.
Novartis (NVS) Announces Positive Data on Kidney Disease Drug
by Zacks Equity Research
Novartis' (NVS) phase III study on pipeline candidate iptacopan in patients with IgAN shows superiority versus placebo in proteinuria reduction.
Is the Options Market Predicting a Spike in Bausch + Lomb (BLCO) Stock?
by Zacks Equity Research
Investors need to pay close attention to Bausch + Lomb (BLCO) stock based on the movements in the options market lately.
Novartis' (NVS) Shareholders Approve Sandoz Separation
by Zacks Equity Research
Novartis' (NVS) shareholders vote in favor of the 100% spin-off of Sandoz into a new publicly traded standalone company.
DocGo Inc. (DCGO) Moves 6.8% Higher: Will This Strength Last?
by Zacks Equity Research
DocGo Inc. (DCGO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
InnovAge Holding Corp. (INNV) Soars 15.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
InnovAge Holding Corp. (INNV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Novartis (NVS) Plans to Spin-Off Sandoz in Early October
by Zacks Equity Research
Novartis (NVS) progresses with the proposed spin-off of its Sandoz arm (scheduled for early October) and invites shareholders for a meeting on the same.
Novartis (NVS) Key Drugs and Pipeline Progress Fuel Growth
by Zacks Equity Research
Novartis (NVS) put up a strong performance year to date based on the solid performance of key drugs and encouraging pipeline progress.
Bausch + Lomb (BLCO) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Bausch + Lomb (BLCO) delivered earnings and revenue surprises of 12.50% and 7.74%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Icon PLC (ICLR) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Icon PLC (ICLR) delivered earnings and revenue surprises of 0.97% and 0.03%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?